Cipla, Dr Reddy’s, Viatris And Teva Named In US Revlimid Antitrust Suit
ANDA Sponsors ‘Restrained Competition And Maintained Shared Monopoly’
Executive Summary
Months after the first generic versions of Bristol-Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) debuted in the US, indirect purchasers of the treatment for multiple myeloma have accused the originator and a raft of settling ANDA sponsors that their deals were anticompetitive.
You may also be interested in...
Reddy’s Exclusivity End Allows Teva, Natco To Match Full US Revlimid Suite
Teva has moved fast to match Dr Reddy’s Laboratories’ complete six-strength offering of generic Revlimid (lenalidomide) products in the US.
Teva Promises New Strategy By The Summer, Washes Hands Of $1bn US Target
Still only six weeks into the job, Teva’s new CEO Richard Francis and his senior team are busy working on a refreshed company strategy, as Teva looks to grow its top line in 2023 for the first time in six years.
MPP’s Guide To Cutting Biosimilar Approval Times, Costs By Third Or More
The Medicines Patent Pool has conducted a study on the impact of licensing and technology transfer on the timeline and costs of developing five biosimilars, including Merck’s Keytruda. While a licensing deal for pembrolizumab might not be a near-term possibility, the findings could help licensors, licensees and regulators increase access to medicines.